Zoledronic acid reduces number of skeletal-related events in new multiple myeloma patients
Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trialLancet Oncol. 2011 Aug;12(8):743-52. doi: 10.1016/S1470-2045(11)70157-7. Epub 2011 Jul 21
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
1960 patients with multiple myeloma were randomized to undergo either intensive or non-intensive treatment. Within each treatment type patients were further randomized to receive either zoledronic acid intravenously or clodronic acid orally, in order to determine which bisphosphonate and treatment type was more effective in lowering the danger of skeletal-related events. Following assessments over...
Join the Conversation
Please Login or Join to leave comments.